BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31468315)

  • 1. Glycopyrronium/Formoterol: A Review in COPD.
    Al-Salama ZT; Frampton JE
    Drugs; 2019 Sep; 79(13):1455-1466. PubMed ID: 31468315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
    Heo YA
    Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
    Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
    Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
    Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study of the effects of Aerochamber Plus
    Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
    Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
    Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease.
    Radovanovic D; Mantero M; Sferrazza Papa GF; Valenti V; Aliberti S; Di Marco F; Santus P
    Expert Rev Respir Med; 2016 Oct; 10(10):1045-55. PubMed ID: 27552524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
    Martinez FJ; Rabe KF; Ferguson GT; Fabbri LM; Rennard S; Feldman GJ; Sethi S; Spangenthal S; Gottschlich GM; Rodriguez-Roisin R; Arora S; Siler TM; Siddiqui S; Darken P; Fischer T; Maes A; Golden M; Orevillo C; Reisner C
    Chest; 2017 Feb; 151(2):340-357. PubMed ID: 27916620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
    Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
    Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
    Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2979-2991. PubMed ID: 31920295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
    Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fixed combination of budesonide, formoterol, glycopyrronium for the treatment of severe COPD : Trixeo Aerosphere®].
    Louis R; Bonhomme O; Heinen V; Nguyen D; Van Cauwenberge H; Corhay JL
    Rev Med Liege; 2022 Apr; 77(4):244-248. PubMed ID: 35389009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Gon Y; Nishi K; Sato K; Maes A; Siddiqui S; Hayashi N; Hirata H; Martin UJ; Reisner C
    Respir Investig; 2021 Jan; 59(1):135-144. PubMed ID: 32917556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
    Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
    Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
    Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P
    Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
    Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
    Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler
    Rabe KF; Martinez FJ; Singh D; Trivedi R; Jenkins M; Darken P; Aurivillius M; Dorinsky P
    Ther Adv Respir Dis; 2021; 15():17534666211034329. PubMed ID: 34428980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.